| 摘要: |
| ［摘要］ 目的 观察小剂量动脉栓塞化疗(TACE)治疗肝癌的临床效果。方法 将2003-12～2014-08该科159例不能手术单病灶原发性肝癌患者随机分为小剂量TACE组94例(A组)和常规剂量TACE组65例（B组）。观察治疗前后两组患者临床症状、肿瘤标志物(AFP)、肿瘤影像学(CT或MRI)、肝功能等变化，评估治疗后临床症状缓解率、肿瘤缩小情况和生存预后。结果 A组、B组治疗后患者的临床症状缓解率分别为76.5%、63.0%，两组比较差异无统计学意义（P=0.065）。术后6个月肿瘤缩小有效率A、B组分别为25.5%（24/94）、29.2%(19/65)，两组比较差异无统计学意义(χ2=0.266，P=0.605)；A组与B组术前甲胎蛋白阳性例数分别为68例、46例，术后1个月甲胎蛋白下降超过50%的比例分别为55.8%(38/68)、52.2%(24/46)，两组比较差异无统计学意义(χ2=0.152，P=0.695)；术后1年生存率A组与B组分别为82.9%（78/94）、75.4%（49/65）,两组比较差异无统计学意义（χ2=1.378，P=0.240）。A组肝功能ALT、AST术后第1、3、5天明显低于B组，差异均有统计学意义，术后第7天A组的ALT、AST基本正常，而B组仍高于正常。结论 小剂量TACE治疗肝癌的疗效与常规剂量TACE无差异，且对肝功能的影响小。 |
| 关键词: 肝癌 动脉栓塞化疗 栓塞 |
| DOI：10.3969/j.issn.1674-3806.2016.09.05 |
| 分类号:R 735.7 |
| 基金项目:广西教育厅科研立项项目（编号：201010LX055） |
|
| The clinical effect of low dose artery chemoembolization on primary liver cancer |
|
JIN Xiao-jian, LU Bang-yu, CAI Xiao-yong, et al.
|
|
Department of General Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ Objective To explore the clinical effect of low dose artery chemoembolization on primary liver cancer.Methods One hundred and fifty-nine patients with advanced primary liver cancer from December 2003 to August 2014 were randomly divided into two groups: group A(n=94) and group B(n=65). Group A was treated with low dose artery chemoembolization and group B was treated with high dose artery chemoembolization. The life quality, clinical response, tumor markers(AFP), tumor imaging(CT or MRI) and liver function changes were observed.Results There was no significant difference in the relief rate of clinical symptoms between group A(76.5%) and group B(63.0%) after the treatment(P=0.065). The tumor shrinking rate was 25.5%(24/94) in group A and 29.2%(19/65) in group B six months after the treatment(χ2=0.266, P=0.605). The positive cases of preoperative AFP were 68 in group A and 46 in group B. The descent rate more than 50.0% was 55.8%(38/68) in group A and 52.2%(24/46) in group B one month after the treatment(χ2=0.152, P=0.695). The survival rate was 82.9%(78/94) in group A and 75.4%(49/65) in group B(χ2=1.378, P=0.240). The postoperative liver function of group A was significant better than that of group B 1, 3 and 5 days after the treatment.Conclusion Low dose and high dose artery chemoembolizations are similarly effective in the treatment of primary liver cancer, but low dose artery chemoembolization has less adverse reactions on liver function. |
| Key words: Liver cancer TACE Embolism |
